Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trial

dc.contributor.authorTweed, Connor D.
dc.contributor.authorDawson, Rodney
dc.contributor.authorBurger, Divan Aristo
dc.contributor.authorConradie, Almari
dc.contributor.authorCrook, Angela M.
dc.contributor.authorMendel, Carl M.
dc.contributor.authorConradie, Francesca
dc.contributor.authorDiacon, Andreas H.
dc.contributor.authorNtinginya, Nyanda E.
dc.contributor.authorEveritt, Daniel E.
dc.contributor.authorHaraka, Frederick
dc.contributor.authorLi, Mengchum
dc.contributor.authorVan Niekerk, Christo H.
dc.contributor.authorOkwera, Alphonse
dc.contributor.authorRassool, Mohammed S.
dc.contributor.authorReither, Klaus
dc.contributor.authorSebe, Modulakgotla A.
dc.contributor.authorStaples, Suzanne
dc.contributor.authorVariava, Ebrahim
dc.contributor.authorSpigelman, Melvin
dc.date.accessioned2020-03-10T09:38:38Z
dc.date.available2020-03-10T09:38:38Z
dc.date.issued2019-12
dc.description.abstractPlease read abstract in the article.en_ZA
dc.description.departmentStatisticsen_ZA
dc.description.librarianhj2020en_ZA
dc.description.sponsorshipTB Alliance, UK Department for International Development, Bill & Melinda Gates Foundation, US Agency for International Development, Directorate General for International Cooperation of the Netherlands, Irish Aid, Australia Department of Foreign Affairs and Trade, and the Federal Ministry for Education and Research of Germany.en_ZA
dc.description.urihttps://www.thelancet.com/journals/lanres/homeen_ZA
dc.identifier.citationTweed, C.D., Dawson, R., Burger, D.A. et al. 2019, 'Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial', Lancet Respiratory Medicine, vol. 7, no. 12, pp. 1048-1058.en_ZA
dc.identifier.issn2213-2600 (print)
dc.identifier.issn2213-2619 (online)
dc.identifier.other10.1016/S2213-2600(19)30366-2
dc.identifier.urihttp://hdl.handle.net/2263/73699
dc.language.isoenen_ZA
dc.publisherElsevieren_ZA
dc.rightsArticle is published Open Access.en_ZA
dc.subjectTuberculosis (TB)en_ZA
dc.subjectBactericidal activityen_ZA
dc.subjectSafety profileen_ZA
dc.subjectPyrazinamideen_ZA
dc.subjectBedaquiline (BDQ)en_ZA
dc.subjectPretomanid (PA‐824)en_ZA
dc.subjectMoxifloxacinen_ZA
dc.subjectPulmonary tuberculosisen_ZA
dc.titleBedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis : a multicentre, open-label, partially randomised, phase 2b trialen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Tweed_ Bedaquiline_2019.pdf
Size:
280.83 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
Thumbnail Image
Name:
Tweed_ BedaquilineSuppl_2019.pdf
Size:
624.31 KB
Format:
Adobe Portable Document Format
Description:
Supplementary appendix
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (Statistics)
Research Articles (University of Pretoria)
Simple item page